Andere Sprachen DiaMedica Therapeutics Inc.

Aktien

A2N9HB

CA25253X2077

DMAC

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:43:05 14.05.2024			% 5 Tage	% 1. Jan.
2,99 ^USD	-6,27 %		-18,03 %	+5,63 %

09.05.	Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
17.04.	DiaMedica Therapeutics Inc. gibt die Verabreichung des ersten Patienten im Rahmen der Wiederaufnahme der Phase-3-ReMEDy2-Studie mit DM199 zur Behandlung des akuten ischämischen Schlaganfalls bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results	08.05.
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024	02.05.
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	17.04.
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	17.04.
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	17.04.
DiaMedica Therapeutics Inc. Announces Executive Changes	10.04.
DiaMedica Therapeutics Files $100 Million Mixed Shelf	21.03.
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results	19.03.
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference	29.01.
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	22.01.
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer	22.01.
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer	22.01.
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results	13.11.
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023	09.11.
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023	06.11.
Top Premarket Gainers	25.10.23
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer	12.09.23
DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer	12.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen DiaMedica Therapeutics Inc.

Aktien

A2N9HB

CA25253X2077

DMAC

Andere Sprachen

Filter